Trial Profile
A Phase II Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms PANDORE
- 19 Jan 2023 Status changed from active, no longer recruiting to completed.
- 19 Feb 2022 Results presented at the 2022 Genitourinary Cancers Symposium
- 03 Jun 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified June 2019).